We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Global Blood (GBT) Q4 Earnings Miss, Revenues Beat Estimates
Read MoreHide Full Article
Global Blood Therapeutics, Inc. incurred a loss of $1 per share in fourth-quarter 2020, narrower than a loss of $1.59 in the year-ago quarter. However, the reported loss was wider than the Zacks Consensus Estimate of a loss of 97 cents.
The company’s revenues of $41.3 million, comprising solely of Oxbryta (voxelotor) sales, beat the Zacks Consensus Estimate of $39 million. The company generated $2.1 million in product sales in the year-ago quarter.
Shares of Global Blood have rallied 13.6% year to date compared with the industry’s increase of 5.4%.
Quarter in Details
Importantly, the company recorded around 950 new prescriptions of Oxbryta in the fourth quarter, despite an increase in COVID-19 cases in the United States during the same time.
Research and development expenses in the fourth quarter were $41.1 million, down 36.7% year over year, primarily attributable to lower expense for capitalization of Oxbryta manufacturing costs to inventory.
Selling, general and administrative expenses were $58.6 million in the reported quarter, up 31.4% year over year due to higher employee-related costs and increased professional and consulting services cost.
As of Dec 31, 2020, Global Blood had cash, cash equivalents and marketable securities worth $560.9 million compared with $535.2 million as of Sep 30, 2020.
Full-Year Results
For 2020, Global Blood generated revenues of $123.8 million, reflecting a significant increase year over year.
For the same period, the company reported loss of $4.04 per share compared with the year-ago loss of $4.57 per share.
Pipeline Update
In January 2021, the European Medicines Agency (“EMA”) completed the validation of Global Blood’s marketing authorization application for Oxbryta tablets and started its standard review process. The company is seeking full marketing approval from the EMA for Oxbryta to treat hemolytic anemia in patients with SCD who are 12 years of age and older. A potential nod in EU should boost Oxbryta sales in the future quarters.
Meanwhile, the company plans to get Oxbryta approved in the United States for the treatment of SCD in children as young as 4 years old.
Global Blood Therapeutics, Inc. Price, Consensus and EPS Surprise
Lexicon’s loss per share estimates have narrowed 74.2% for 2021 over the past 60 days. The stock has skyrocketed 126.5% year to date.
Vericel’s earnings estimates have been revised 11.7% upward for 2021 over the past 60 days. The stock has rallied 60.2% year to date.
Dynavax’s loss per share estimates have narrowed 62.2% for 2021 over the past 60 days. The stock has soared 110.8% year to date.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Image: Bigstock
Global Blood (GBT) Q4 Earnings Miss, Revenues Beat Estimates
Global Blood Therapeutics, Inc. incurred a loss of $1 per share in fourth-quarter 2020, narrower than a loss of $1.59 in the year-ago quarter. However, the reported loss was wider than the Zacks Consensus Estimate of a loss of 97 cents.
The company’s revenues of $41.3 million, comprising solely of Oxbryta (voxelotor) sales, beat the Zacks Consensus Estimate of $39 million. The company generated $2.1 million in product sales in the year-ago quarter.
Shares of Global Blood have rallied 13.6% year to date compared with the industry’s increase of 5.4%.
Quarter in Details
Importantly, the company recorded around 950 new prescriptions of Oxbryta in the fourth quarter, despite an increase in COVID-19 cases in the United States during the same time.
Research and development expenses in the fourth quarter were $41.1 million, down 36.7% year over year, primarily attributable to lower expense for capitalization of Oxbryta manufacturing costs to inventory.
Selling, general and administrative expenses were $58.6 million in the reported quarter, up 31.4% year over year due to higher employee-related costs and increased professional and consulting services cost.
As of Dec 31, 2020, Global Blood had cash, cash equivalents and marketable securities worth $560.9 million compared with $535.2 million as of Sep 30, 2020.
Full-Year Results
For 2020, Global Blood generated revenues of $123.8 million, reflecting a significant increase year over year.
For the same period, the company reported loss of $4.04 per share compared with the year-ago loss of $4.57 per share.
Pipeline Update
In January 2021, the European Medicines Agency (“EMA”) completed the validation of Global Blood’s marketing authorization application for Oxbryta tablets and started its standard review process. The company is seeking full marketing approval from the EMA for Oxbryta to treat hemolytic anemia in patients with SCD who are 12 years of age and older. A potential nod in EU should boost Oxbryta sales in the future quarters.
Meanwhile, the company plans to get Oxbryta approved in the United States for the treatment of SCD in children as young as 4 years old.
Global Blood Therapeutics, Inc. Price, Consensus and EPS Surprise
Global Blood Therapeutics, Inc. price-consensus-eps-surprise-chart | Global Blood Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Global Bloodcurrently carries a Zacks Rank #4 (Sell). Better-ranked stocks in the biotech sector include Lexicon Pharmaceuticals, Inc. (LXRX - Free Report) , Vericel Corporation (VCEL - Free Report) and DynavaxTechnologies Corporation (DVAX - Free Report) , all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Lexicon’s loss per share estimates have narrowed 74.2% for 2021 over the past 60 days. The stock has skyrocketed 126.5% year to date.
Vericel’s earnings estimates have been revised 11.7% upward for 2021 over the past 60 days. The stock has rallied 60.2% year to date.
Dynavax’s loss per share estimates have narrowed 62.2% for 2021 over the past 60 days. The stock has soared 110.8% year to date.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Click here for the 4 trades >>